Clinical observation about anti-virus therapy of entecavir in treating chronic hepatitis B at the initial stage

Objective To evaluate the 48 weeks therapeutic effects and safety of anti-virus therapy of entecavir in patients with chronic hepatitis B(CHB).Methods 187 CHB cases were divided into the treated group(118) and the control group (69) randomly.Patients were given entecarvir(0.5mg po qd) in the treated group,while the others were given lamivudine (100mg po qd) in the control group.Results In the treated group,the levels of serum HBV DNA was obviously decreased thanthat before treatment at the 4thand 8thweek;at the 12thweek,the ratio of negative transformation of HBV DNA was 57.6%,which was superior to the control group,there was higher ratio of early reponse of anti-virus therapy;at the 24thand 48thweek,the ratios of negative transformation of HBV DNA were 81.3% and 92.3%,there were significent difference between these twogroups;at the 48thweek the ratio of negative transformation of HBeAg was separately 28.8% and the ratio of recovery of liver function was 98.3%,and there was no drug-resistant case,it demonstrated favourable reaction of sustained response.There was no serious adverse event related with entecavir.Conclusion Entecavir can inhibit the replication of hepatitis B virus and have good safety and tolerance.